WST West Pharmaceutical Services
Wonderful moat, but priced for fantasy growth I cannot underwrite.
The business
West Pharmaceutical Services makes proprietary containment and delivery components (stoppers, syringes, vials) for injectable drugs and biologics. Pharma customers deeply integrate West's components into their drug filings, creating high switching costs. Revenue scales with the volume of injectable/biologic drugs approved and administered globally.
Quality gate · 84/100
Moat & management
| Moat | wide moat |
| Source | switching costs |
| Trajectory | stable |
| Management | adequate |
Once a pharma company validates West's components in a regulatory filing, changing suppliers requires re-validation, new filings, and potential bridging studies — making switching prohibitively costly and risky. The secular shift toward biologics and self-administration devices reinforces West's position, though post-COVID demand normalization has temporarily muted growth.
Conservative balance sheet with net cash and modest buybacks, but capital allocation score is the weakest quality component. Reinvestment in high-value-product capacity is sensible, though they don't aggressively repurchase stock at any price.
Owner-earnings inputs
| Owner earnings (TTM) | 436.90M |
| Owner-earnings yield | 1.8% |
| Free-cash-flow yield | 1.8% |
| Growth used (normalized) | 7.0% |
| Market-implied growth (reverse DCF) | 25.0% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 9.8% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 448.81M | 7.0% | 408.85M |
| 2 | 478.94M | 6.7% | 397.45M |
| 3 | 509.73M | 6.4% | 385.34M |
| 4 | 541.05M | 6.1% | 372.59M |
| 5 | 572.74M | 5.9% | 359.30M |
| 6 | 604.65M | 5.6% | 345.54M |
| 7 | 636.61M | 5.3% | 331.42M |
| 8 | 668.44M | 5.0% | 317.00M |
| 9 | 699.95M | 4.7% | 302.39M |
| 10 | 730.95M | 4.4% | 287.67M |
| 11 | 761.23M | 4.1% | 272.91M |
| 12 | 790.59M | 3.9% | 258.20M |
| 13 | 818.82M | 3.6% | 243.61M |
| 14 | 845.73M | 3.3% | 229.21M |
| 15 | 871.10M | 3.0% | 215.07M |
Key risks
- Stock prices in ~25% growth — extreme valuation risk if growth disappoints even modestly
- Post-COVID normalization has already compressed revenue CAGR to ~2%; recovery timing uncertain
- Large pharma customer concentration and potential in-sourcing or alternative materials adoption
Catalysts
- Biologics pipeline approvals driving demand for high-value containment systems
- Shift toward self-administration devices (auto-injectors, wearable injectors) where West has proprietary platforms
Recent news
score · 8 articles
- SNN Advances Surgical Robotics Through Imperial College Partnership
- HNGE Stock Surges Nearly 90% YTD: Can Its Growth Story Continue?
- Intuitive Surgical Expands Manufacturing Footprint in Asia Pacific
- Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
- Smith+Nephew Launches FLOW FLEXTEND COBLATION Wand for Hip Surgery
- Here's Why You Should Retain CONMED Stock in Your Portfolio Now
- Natera Supports Kupando Trial to Advance ctDNA Monitoring in Cancer
- WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Net cash 0.5B credited to value (interest stripped from owner earnings to avoid double-counting). · Price pays for ~25%/yr owner-earnings growth over 15y (reverse DCF); model credits 7%. · Rich vs our conservative value, but a quality business is not a short — stance is WAIT for a better price, not sell.